title: [On the brink of a new era in the treatment of chronic hepatitis C virus infection in Denmark].
abstract: Treatment of chronic hepatitis C virus (HCV) has for more than a decade been based upon use of pegylated interferon in combination with ribavirin. Sustained virologic response rates are in general at a moderate level and severe adverse effects are frequent. With the introduction of direct acting antivirals (DAA) we now face the possibility of interferon-free treatment with higher response rates and less severe adverse effects. However, the costs of the DAAs are high presenting an additional economical burden to the health sector calling for necessary priorities to be taken.
authors.forename: Andreas Halgreen
authors.initials: AH
authors.lastname: Eiset
authors.forename: Maibritt Provstgaard
authors.initials: MP
authors.lastname: Holm
authors.affiliation: Infektionsmedicinsk Afdeling Q, Aarhus Universitetshospital, Brendstrupgårdsvej 100, 8200 Aarhus N. E-mail: peteleut@rm.dk.
authors.forename: Peter Derek Christian
authors.initials: PD
authors.lastname: Leutscher
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003718:Denmark; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000191:economics; D016174:Hepacivirus / Q000187:drug effects / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D014542:Uridine Monophosphate